{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T12:13:39Z","timestamp":1783167219440,"version":"3.54.6"},"reference-count":61,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Global Public Health"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1080\/17441690601063299","type":"journal-article","created":{"date-parts":[[2007,5,24]],"date-time":"2007-05-24T14:40:19Z","timestamp":1180017619000},"page":"184-203","source":"Crossref","is-referenced-by-count":14,"title":["Pharmacovigilance and new essential drugs in Africa: Zambia draws lessons from its own experiences and beyond"],"prefix":"10.1080","volume":"2","author":[{"given":"M.","family":"Huff-Rousselle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Simooya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Kabwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Handema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mwango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mwape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200326030-00001"},{"key":"CIT0002","unstructured":"American Public Health Association ( 2003 ) Supporting Legislation for Independent Post-marketing (Phase IV) Comparative Evaluation of Pharmaceuticals .APHA Policy Statement 2003-1. Accessed 7 May 2006, available at http:\/\/apha.org\/legislative\/policy\/2003\/2003-001.pdf"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp058174"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1001\/jama.274.1.29"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1001\/jama.277.4.307"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1557(199701)6:1<21::AID-PDS259>3.0.CO;2-I"},{"key":"CIT0007","volume-title":"Zambia. The World Factbook","year":"2005"},{"key":"CIT0008","volume-title":"Zambia Demographic and Health Survey","year":"2002"},{"key":"CIT0009","unstructured":"Chikwenya , N. , Mtonga , S. , Bwembya , M. , Andala , R. , Chansa , C. , Broms , C. et al. ( 2004 ) Proposal to Establish a Drug Supply Account: Towards Financial Sustainability for Drugs and Laboratory Supplies in the Public Health Sector . Government of Republic of Zambia, Ministry of Health ."},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1001\/jama.277.4.301"},{"key":"CIT0011","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMra025195","volume":"350","author":"Clavel F.","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"CIT0012","unstructured":"Committee on Safety of Medicines and Medicines Control Agency ( 2002 ) Suspected Adverse Reaction (ADR) Reporting and the Yellow Card Scheme (Guidance Notes for Nurses). Committee on Safety of Medicines and Medicines Control Agency . Accessed 18 September 2005, available at http:\/\/www.mca.gov.uk\/ourwork\/monitorsafequalmed\/yellowcard\/ycguidancenotes.pdf"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.1.89"},{"key":"CIT0014","author":"Drucker P.F.","year":"1967","journal-title":"The Harvard Business Review"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199410020-00001"},{"key":"CIT0016","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/bmj.313.7056.530","volume":"313","author":"Egberts T.C.G.","year":"1996","journal-title":"British Medical Journal"},{"key":"CIT0017","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1177\/106002809302700702","volume":"27","author":"Einarson T.R.","year":"1993","journal-title":"The Annals of Pharmacotherapy"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.21.2647"},{"key":"CIT0022","first-page":"57","author":"Gaynor C.","year":"2005","journal-title":"Tr\u00f3caire Development Review"},{"key":"CIT0023","unstructured":"Government of Republic of Zambia ( 2004 ) The Pharmaceutical Act, 2004 . No 14 of 2004. Government of Republic of Zambia , 91 \u2013 128 ."},{"key":"CIT0024","unstructured":"Government of Republic of Zambia and Ministry of Health ( 2004 ) National Health Strategic Plan 2001\u20132005, Mid Term Review Report . Ministry of Health, Government of the Republic of Zambia ."},{"key":"CIT0025","unstructured":"Government of Republic of Zambia and Ministry of Health ( 2005 ) Free Antiretroviral Drugs (ARVs) Operational Guidelines for Health Facilities in Zambia . Ministry of Health, Government of the Republic of Zambia ."},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2005.03.027"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2005.03.046"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04776-0"},{"key":"CIT0029","unstructured":"Huff-Rousselle , M. ( 2005 ) Starting from Scratch in Timor Leste: Establishing a Pharmaceutical and Medical Supplies System in a Post-Conflict Context . The World Bank ."},{"key":"CIT0030","unstructured":"Huff-Rousselle , M. and Kabwe , V. ( 2006 ) Following the Coartem\u00ae Trail in Zambia: Anxious Aspirations & Practical Problems in Rolling Back Malaria . Submitted for publication ."},{"key":"CIT0031","unstructured":"Huff-Rousselle , M. , Kabwe , V. and Chikwenya , N. ( 2006 ) Health Sector Reform and Pharmaceutical Supply: A Zambian Case Study . Submitted for publication ."},{"key":"CIT0032","unstructured":"Huff-Rousselle , M. , Kabwe , V. , Nunn , A. and Simooya , O. ( 2005 ) Pharmacovigilance in Zambia Part I: Rationale, Organizational Roles and Responsibilities, and Basic Reporting System. Working document prepared for Technical Pharmacovigilance Working Group . Health Services and Systems Program ."},{"key":"CIT0033","unstructured":"International Society of Drug Bulletins ( 2005 ) ISDB EU: Berlin Declaration on Pharmacovigilance . International Society of Drug Bulletins ."},{"key":"CIT0034","author":"Kaunda B.","year":"2005","journal-title":"Zambia Daily Mail"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000174445.40379.e0"},{"key":"CIT0036","unstructured":"Kombe , G. , Galaty , D. , Mtonga , V. and Banda , P. ( 2005 ) Human Resources Crisis in the Zambian Health System: A Call for Urgent Action. Abt Associates , PHRplus Project, Order No. TE 071 ."},{"key":"CIT0037","author":"Krasner J.","year":"2002","journal-title":"The Boston Globe"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.17.2215"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.15.1200"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.329.7477.1253"},{"key":"CIT0041","unstructured":"Lindquist , M. ( 2004 , May ) The WHO Adverse Reaction Database . Uppsala Monitoring Centre ."},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7519.706"},{"key":"CIT0043","unstructured":"Medicines Control Council ( 2004 ) Adverse Drug Reactions Reporting Form . Department of Health, Republic of South Africa. Document: 6.04 ARF1 May 03 v2.doc ."},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199921060-00001"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200022060-00001"},{"key":"CIT0046","unstructured":"Ministry of Health ( 2005 ) Medium-Term Procurement Plan 2005\u20132007 . Ministry of Health , Lusaka, Zambia ."},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00667.x"},{"key":"CIT0048","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/bmj.316.7140.1295","volume":"316","author":"Pirmohamed M.","year":"1998","journal-title":"British Medical Journal"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.21.2622"},{"key":"CIT0050","unstructured":"Roberts , P. ( 1994 ) Adverse Drug Reactions (ADRs). A Distance Learning Pack for Community Pharmacists . Centre for Pharmacy Postgraduate Education ."},{"key":"CIT0051","unstructured":"Sasich , L.D. ( 2000 , September 15 ) Comments before the FDA's Public Meeting on the Prescription Drug User Fee Act (PDUFA) . Public Citizen's Health Research Group ."},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528040-00001"},{"key":"CIT0053","unstructured":"United Nations Development Programme ( 2004 ) Human Development Report 2004: Cultural Liberty in Today's Diverse World . United Nations Development Programme ."},{"key":"CIT0054","unstructured":"Uppsala Monitoring Centre and World Health Organization ( 2000 ) Safety Monitoring of Medical Products: Guidelines for Setting up and Running a Pharmacovigilance Centre . Uppsala Monitoring Centre and the World Health Organization ."},{"key":"CIT0055","unstructured":"Uppsala Monitoring Centre and World Health Organization ( 2002 ) The Importance of Pharmacovigilance: Safety Monitoring of Medical Products . Uppsala Monitoring Centre and the World Health Organization ."},{"key":"CIT0056","unstructured":"Uppsala Monitoring Centre and World Health Organization ( 2006 ) WHO Programme. Uppsala Monitoring Centre and the World Health Organization . Accessed 25 August 2006, available at http:\/\/www.who-umc.org\/DynPage.aspx?id=13140&mn=1514#4"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb053432"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16043-1"},{"key":"CIT0059","first-page":"1","author":"Willman D.","year":"2000","journal-title":"Los Angeles Times"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1211\/0022357991772466"},{"key":"CIT0061","unstructured":"World Health Organization ( 1998 ) Report on the International Workshop on Counterfeit Drugs . World Health Organization, 26\u201328 November, WHO\/DRS\/CDF\/98.1"},{"key":"CIT0062","unstructured":"World Health Organization ( 2002 ) The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products . World Health Organization ."},{"key":"CIT0063","unstructured":"World Health Organization ( 2004a ) The Selection and Use of Essential Medicines. Report of the WHO Expert Committee, 2003 . World Health Organization, WHO Technical Report Series No. 920 ."},{"key":"CIT0064","unstructured":"World Health Organization ( 2004b ) Malaria and HIV Interactions and their Implications for Public Health Policy. Report of Technical Consultation. World Health Organization . Department of HIV\/AIDS and Roll Back Malaria Department ."}],"container-title":["Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17441690601063299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,28]],"date-time":"2019-04-28T04:36:22Z","timestamp":1556426182000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/17441690601063299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["10.1080\/17441690601063299"],"URL":"https:\/\/doi.org\/10.1080\/17441690601063299","relation":{},"ISSN":["1744-1692","1744-1706"],"issn-type":[{"value":"1744-1692","type":"print"},{"value":"1744-1706","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}